Trial Profile
Pivotal phase III trial of entinostat in combination with erlotinib in patients with non-small cell lung cancer who have elevated E-cadherin levels.
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 13 Dec 2011
Price :
$35
*
At a glance
- Drugs Entinostat (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Biomarker; Registrational; Therapeutic Use
- 13 Dec 2011 New trial record